Biocure Technology Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a BICTF research report →
About the company
Biocure Technology Inc. , along with its subsidiary, is dedicated to the development and market introduction of biopharmaceutical technologies, particularly those leveraging recombinant proteins and ranibizumab. The company's therapeutic pipeline features Interferons-ß, which are being advanced for the treatment of multiple sclerosis.
- CEO
- Yee Sing Cheng
- IPO
- 2018
- Employees
- 3
- HQ
- Vancouver, BC, CA
Price Chart
- Market Cap
- $379.09K
- P/E
- -2.79
- P/S
- 0.00
- P/B
- 0.18
- EV/EBITDA
- -6.12
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -6.94%
- ROIC
- -5.57%
- Revenue
- $0 · 0.00%
- Net Income
- $-102,776 · 60.84%
- EPS
- $-0.01 · 74.50%
- Op Income
- $-90,789
- FCF YoY
- -557603.28%
- 52W High
- $0.07
- 52W Low
- $0.01
- 50D MA
- $0.01
- 200D MA
- $0.01
- Beta
- 3.83
- Avg Volume
- 648
Get TickerSpark's AI analysis on BICTF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our BICTF coverage
Recent articles, reports, and earnings notes.
No research on BICTF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate BICTF report →Similar companies
Peers in the same neighborhood.